| Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.BMC Nephrol | PMID 35135481PMC8826669 | 2022-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.J Headache Pain | PMID 35130836PMC8903490 | 2022-Feb-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.Lancet | PMID 35093205PMC8797010 | 2022-Feb-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).Trials | PMID 35123553PMC8817533 | 2022-Feb-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.Lancet | PMID 35123694PMC8819271 | 2022-Feb-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.N Engl J Med | PMID 35045221PMC11651366 | 2022-Feb-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.N Engl J Med | PMID 35108470无 PMCID | 2022-Feb-03 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study.Haematologica | PMID 34134469PMC8804572 | 2022-Feb-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.Am J Hematol | PMID 34724251无 PMCID | 2022-Feb-01 | 0.85 | This is a primary result report from a randomized Phase III oncology trial (MDS) with a drug intervention. However, it is excluded because the primary efficacy endpoint is a response rate (proportion achieving transfusion independence), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, or any endpoint analyzed via Kaplan-Meier or reported as a hazard ratio. | 待处理 |
| Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.J Clin Oncol | PMID 34730989无 PMCID | 2022-Feb-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.J Clin Oncol | PMID 34855460PMC8797487 | 2022-Feb-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 34882169PMC8662535 | 2022-Feb-01 | 0.90 | The trial is a phase 3 randomized oncology study with a drug intervention and reports original primary results. However, the primary efficacy endpoint is a change in fatigue score, which is not a time-to-event endpoint. The criteria require a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis). This study lacks that specific endpoint. | 待处理 |
| Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.JAMA Oncol | PMID 34913959PMC8678901 | 2022-Feb-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.JAMA Oncol | PMID 34940781PMC8855230 | 2022-Feb-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.Obstet Gynecol | PMID 34991145PMC9126568 | 2022-Feb-01 | 0.95 | The record is an eligible oncology, human, randomized, Phase III trial with time-to-event analytical methods, but it is excluded because it is a secondary analysis (focused on symptom presentation, not the trial's primary efficacy endpoint) and lacks clear evidence of a drug-containing intervention. | 待处理 |
| Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.JAMA | PMID 35029629PMC8808333 | 2022-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.BMC Cancer | PMID 35105329PMC8808992 | 2022-Feb-01 | 0.45 | The study is a randomized Phase III oncology trial with a drug intervention (biosimilar bevacizumab) and reports original results, but the primary efficacy endpoint is overall response rate (ORR), not a time-to-event endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). The deterministic review correctly identified the absence of time-to-event signal. | 待处理 |
| Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.J Drugs Dermatol | PMID 35133113无 PMCID | 2022-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial.JAMA Netw Open | PMID 35226081PMC8886520 | 2022-Feb-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer.JAMA Netw Open | PMID 35226083PMC8886546 | 2022-Feb-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.Diabetes Obes Metab | PMID 34647404PMC9299227 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials.J Dermatolog Treat | PMID 32347763无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials.J Dermatolog Treat | PMID 32419536无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab.Arthritis Care Res (Hoboken) | PMID 32937016无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis.Clin Gastroenterol Hepatol | PMID 33279779PMC8588993 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda.Sex Transm Infect | PMID 33542153PMC8785055 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis.Int J Stroke | PMID 33724104无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sustained-release isosorbide mononitrate as adjuvant treatment in isolated systolic hypertension in the elderly.J Hum Hypertens | PMID 33850272无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER.Ophthalmol Retina | PMID 33971353无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation.Reprod Sci | PMID 34363198PMC8345905 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.Clin Pharmacokinet | PMID 34379314PMC8813705 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized trial of two maintenance doses of vitamin D in children with chronic kidney disease.Pediatr Nephrol | PMID 34392411无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.Prostate Cancer Prostatic Dis | PMID 34420037无 PMCID | 2022-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.Clin Pharmacokinet | PMID 34431071PMC8813707 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study.J Clin Pharmacol | PMID 34524700PMC9303933 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.J Rheumatol | PMID 34526397无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.Lancet Infect Dis | PMID 34534511PMC8439621 | 2022-Feb | 0.95 | Eligible on human, randomized, phase 3, drug intervention, and original result criteria, but excluded because it is not an oncology trial and lacks the required time-to-event efficacy endpoint. | 待处理 |
| A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.Kidney Int | PMID 34560137无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children.Acta Paediatr | PMID 34606114PMC9297935 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.Br J Cancer | PMID 34616010PMC8770703 | 2022-Feb | 0.85 | The record is from a secondary analysis of genome-wide association data from multiple phase III randomized oncology trials, but it does not report survival, progression, recurrence, death, hazard, or other time-to-event efficacy outcomes required for inclusion. | 待处理 |
| Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.J Eur Acad Dermatol Venereol | PMID 34634163PMC9297965 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.J Thorac Oncol | PMID 34648948无 PMCID | 2022-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.Clin Pharmacol Ther | PMID 34674258无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).BJOG | PMID 34676663PMC9299454 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study.Clin Lymphoma Myeloma Leuk | PMID 34686445无 PMCID | 2022-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial.Bone Marrow Transplant | PMID 34728786PMC8821013 | 2022-Feb | 0.95 | The trial is a randomized, blinded, Phase III oncology trial in humans with original results, but it evaluates a cooling device (device vs. ice) and does not include a drug-containing intervention. The primary endpoint is a patient-reported symptom score (Oral Mucositis Assessment Scale), not a time-to-event efficacy endpoint like OS, PFS, or similar. | 待处理 |
| Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.Rheumatol Int | PMID 34773130无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial.Lancet Respir Med | PMID 34774185PMC8585489 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes.Transplant Cell Ther | PMID 34775146PMC8882346 | 2022-Feb | 0.85 | The report describes a Phase III randomized trial with human oncology patients and time-to-event endpoints (PFS, OS), but the intervention is transplantation with graft types (UCB, Haplo-BM), not a drug-containing regimen. The inclusion criteria require a drug-containing intervention, which is not explicitly established here. | 待处理 |
| Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.Lancet Gastroenterol Hepatol | PMID 34798038无 PMCID | 2022-Feb | 0.95 | Study is a Phase III randomized trial of etrolizumab vs. infliximab in ulcerative colitis (a non-malignant inflammatory bowel disease). The primary endpoint is clinical response/remission, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). | 待处理 |